Cellular escape artists help explain why some women present with advanced ovarian cancer
(Brigham and Women's Hospital) In a new study published recently in The Journal of Pathology, BWH investigators conducted an exhaustive analysis of 'normal' fallopian tubes from patients with HGSC. Their analysis indicates that normal appearing tubes can contain pre-cancerous cells may escape the tubes, later progressing to cancer in the pelvic or abdominal cavity. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 13, 2018 Category: Cancer & Oncology Source Type: news

Tumor Treating Fields Also Show Efficacy in Ovarian Cancer Tumor Treating Fields Also Show Efficacy in Ovarian Cancer
In a phase 2 trial, patients treated with electromagnetic fields and paclitaxel fared better than historical patients treated with paclitaxel alone. The device is approved for treating brain cancer.electromagnetic field therapyMedscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Researchers Find New Mesothelioma Genes in Family Study
This study strengthens the suspicion that, next to germline BAP1 alterations, other genetic factors might predispose families to the development of MM,” the authors wrote. Mutations in only one gene called BAP1 have been shown to increase risk of mesothelioma. However, experts suspect other genes may play a role in the disease. This new study supports the idea that other genes can predispose a person — or even an entire family — to mesothelioma. Hints of Genetic Influence on Mesothelioma Risk Asbestos exposure is the No. 1 cause of mesothelioma. However, some families seem to have more cases of mesothe...
Source: Asbestos and Mesothelioma News - August 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Doxorubicin disrupts the immune system to cause heart toxicity
(University of Alabama at Birmingham) Doxorubicin is a chemotherapy drug used in ovarian, bladder, lung, thyroid and stomach cancers, but it carries a harmful side effect. The drug causes a dose-dependent heart toxicity that can lead to congestive heart failure. Researchers have found an important contributor to that heart pathology -- disruption of the metabolism that controls immune responses in the spleen and heart. This dysregulated immunometabolism impairs resolution of inflammation, and chronic, non-resolving inflammation leads to advanced heart failure. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - August 6, 2018 Category: Biology Source Type: news

Epigenetic markers of ovarian cancer
(InSilico Medicine, Inc.) Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes. The study reveals 43 genes abnormally methylated in ovarian cancer and identifies methylation of an engulfment gene, GULP1, as a potential biomarker of ovarian cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 6, 2018 Category: International Medicine & Public Health Source Type: news

Medical News Today: Ovarian cancer and weight gain: What's the link?
Some people with ovarian cancer may experience weight gain. Bloating, certain treatments for cancer, or changes in lifestyle after diagnosis could be linked to this weight gain. In this article, we look at the link between weight gain and ovarian cancer and consider some tips for weight management. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 1, 2018 Category: Consumer Health News Tags: Ovarian Cancer Source Type: news

Medical News Today: Can ovarian cysts become cancerous?
Ovarian cysts are fluid-filled sacs that can develop in the ovaries. They are often harmless and require no treatment. However, they can sometimes cause symptoms similar to ovarian cancer or, rarely, become cancerous themselves. A doctor may surgically remove an ovarian cyst that is causing problems. Learn more here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 1, 2018 Category: Consumer Health News Tags: Ovarian Cancer Source Type: news

U.S. insurers grilled on exposure to $4.7 billion J & J talc verdict
Wall Street is trying to figure out whether the U.S. insurance industry will bear any costs from a record $4.69 billion judgment against Johnson& Johnson awarded to customers and their families who claimed that asbestos-contaminated talc caused ovarian cancer. (Source: Reuters: Health)
Source: Reuters: Health - July 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Aspirin/NSAID Use and Improved Survival in Ovarian Cancer Aspirin/NSAID Use and Improved Survival in Ovarian Cancer
Women who reported used aspirin or NSAIDs following a diagnosis of ovarian cancer showed an improved disease-specific survival compared with those who did not.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Numerous lawsuits claim link between baby powder and ovarian cancer, so is it safe or not?
While some suits already heard in the U.S. have resulted in compensation, studies on talcum powder's potential link to the gynecological cancer have produced often contrary conclusions. (Source: CBC | Health)
Source: CBC | Health - July 30, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Fertility Often Preserved in Female Childhood-Cancer Survivors Fertility Often Preserved in Female Childhood-Cancer Survivors
Most female childhood-cancer survivors (CCSs) show normal hormonal and ultrasound markers of ovarian reserve, according to Dutch researchers.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 30, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Targeting gene mutations to treat ovarian cancers
(Westmead Institute for Medical Research) New research has shown that ovarian cancer patients with a tumour mutation in the BRAF gene respond exceptionally well to treatment with targeted drugs, known as BRAF inhibitors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 30, 2018 Category: International Medicine & Public Health Source Type: news

Breastfeeding support services 'failing mothers' due to cuts
Campaign group finds at least 44% of local authority areas in England affected by recent cuts to breastfeeding servicesNew mothers across England are being failed as a result of cuts to local breastfeeding support services, campaigners say.Breastfeeding is known to reduce the risk of infections and allergies as well as future obesity and diabetes for the baby, while benefits to mothers include a reduced risk of breast and ovarian cancer.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - July 27, 2018 Category: Science Authors: Nicola Davis Tags: Breastfeeding Health & wellbeing Life and style Parents and parenting Family Society Source Type: news

Taking aspirin just twice a week reduces a woman ’s risk of ovarian cancer by 10%
EXCLUSIVE Researchers from the National Cancer Institute and Moffitt Cancer Center believe that as an anti-inflammatory drug, aspirin prevents DNA damage that causes cancer to develop. (Source: the Mail online | Health)
Source: the Mail online | Health - July 27, 2018 Category: Consumer Health News Source Type: news

Ovarian Epithelial Fallopian Tube Cancer Treatment
Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 26, 2018 Category: General Medicine Source Type: news

Tumor Vasculature Remains Stable Through Progression of Ovarian Cancer
The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression. (Source: CancerNetwork)
Source: CancerNetwork - July 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Fertility treatment doesn't boost overall risk of breast, ovary or uterus cancers
(Reuters Health) - Assisted reproductive technologies don't carry an overall increased risk of breast, ovarian or uterine cancer, according to a new study in the UK. (Source: Reuters: Health)
Source: Reuters: Health - July 24, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Why AdaptImmune collected $27.5M from GSK
Adaptimmune received a $27.5 million payment from GlaxoSmithKline following the transitioning of a T-cell therapy program targeted solid tumors from one company to the other. As a result of the transition, GSK has assumed full responsibility for the future research, development, and potential commercialization of Adaptimmune's NY-ESO SPEAR T-cell therapy being looked as a potential treatment for a variety of cancers including non-small cell lung cancer, metastatic mela noma, ovarian and multiple… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 24, 2018 Category: Biotechnology Authors: John George Source Type: news

NHS Health Heroes: The ovarian cancer expert who treats women 'written-off' by other doctors
Professor Jayson, who ’s worked at The Christie in Manchester since 1992, is the type of consultant who is always available by email day or night, say his patients. (Source: the Mail online | Health)
Source: the Mail online | Health - July 23, 2018 Category: Consumer Health News Source Type: news

Does Analgesic Use Improve Survival in Ovarian Cancer?
Recent use of aspirin or NSAIDs is associated with improved ovarian cancer –specific survival. (Source: CancerNetwork)
Source: CancerNetwork - July 23, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Johnson & Johnson will appeal $4.7B powder award
Johnson& Johnson says it will "pursue all available appellate remedies" to reverse a St. Louis court verdict that awarded $4.7 billion to women who alleged that using the company ’s baby powder caused their ovarian cancer.  In a prepared statement, J&J (NYSE:JNJ) contends that the lawsuit filed on behalf of 22 women should not have been heard in Missouri because many of the women were not from the state.   Company spokeswoman Carol Goodrich predicted a reversal, saying, “The multiple errors… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 23, 2018 Category: American Health Authors: Anne Stych Source Type: news

Low-Dose Aspirin May Help Against Ovarian Cancer
One low-dose aspirin -- the type many older women already take to help their hearts -- was tied to a 10 percent reduction in developing ovarian cancer and as much as a 30 percent improvement in survival for ovarian cancer patients, two new studies have found. (Source: WebMD Health)
Source: WebMD Health - July 20, 2018 Category: Consumer Health News Source Type: news

Daily Low - Dose Aspirin May Be Weapon Against Ovarian Cancer
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2018 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Daily Low-Dose Aspirin May Be Weapon Against Ovarian Cancer
FRIDAY, July 20, 2018 -- One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest. In fact, daily low-dose aspirin -- the type many older women already take to help their... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2018 Category: General Medicine Source Type: news

Daily Low-Dose Aspirin May Be Weapon Against Ovarian Cancer
Title: Daily Low-Dose Aspirin May Be Weapon Against Ovarian CancerCategory: Health NewsCreated: 7/20/2018 12:00:00 AMLast Editorial Review: 7/20/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 20, 2018 Category: Cancer & Oncology Source Type: news

Daily Low-Dose Aspirin May Be Weapon Against Ovarian Cancer
(Source: Cancercompass News: Gynecological Cancer)
Source: Cancercompass News: Gynecological Cancer - July 20, 2018 Category: Cancer & Oncology Source Type: news

Link for Asbestos - Free Talcum Powder, Cancer Not Clear
Studies conducted in people have mixed results, with some indication of increased risk of ovarian cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 19, 2018 Category: Cancer & Oncology Tags: Family Medicine, Gynecology, Nursing, Oncology, Pathology, Pharmacy, Institutional, Source Type: news

Using PARP Inhibitors in Advanced Ovarian Cancer
The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment. (Source: CancerNetwork)
Source: CancerNetwork - July 18, 2018 Category: Cancer & Oncology Authors: Roisin E. O ’Cearbhaill, MD Source Type: news

Trial Adds Gemcitabine to Pleural Mesothelioma HIOC Therapy
Results of a phase I clinical trial highlight how the addition of a drug to an existing treatment option appears safe and may improve outcomes in certain patients with malignant pleural mesothelioma (MPM). The primary goal of the trial was to determine the maximum tolerated dose of gemcitabine added to cisplatin when these drugs are delivered together as heated intraoperative chemotherapy (HIOC) during surgery. Researchers have studied cisplatin alone for HIOC. The addition of gemcitabine — a chemotherapy drug often used to treat pancreatic, ovarian and breast cancers — is new. The Journal of Thoracic Oncology...
Source: Asbestos and Mesothelioma News - July 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Scientists discover a mechanism of drug resistance in breast and ovarian cancer
(Rockefeller University) A new study helps explain why certain cancers don't respond to treatment, and offers hope for overcoming this deadly resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 18, 2018 Category: Cancer & Oncology Source Type: news

Higher Risk of In - Situ Breast CA, Ovarian Tumors With Fertility Tx
No increased risk of corpus uteri, invasive breast cancer for women undergoing assisted reproduction (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 17, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news

Higher Risk of In-Situ Breast CA, Ovarian Tumors With Fertility Tx
TUESDAY, July 17, 2018 -- For women undergoing assisted reproduction, there is no increased risk of corpus uteri or invasive breast cancer, but there is an increased risk of ovarian cancer and in situ breast cancer, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 17, 2018 Category: Pharmaceuticals Source Type: news

Johnson & Johnson will appeal $4.7B powder award
Johnson& Johnson says it will "pursue all available appellate remedies" to reverse a St. Louis court verdict that awarded $4.7 billion to women who alleged that using the company ’s baby powder caused their ovarian cancer.  In a prepared statement, J&J (NYSE:JNJ) contends that the lawsuit filed on behalf of 22 women should not have been heard in Missouri because many of the women were not from the state.   Company spokeswoman Carol Goodrich predicted a reversal, saying, “The multiple errors… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - July 16, 2018 Category: Health Management Authors: Anne Stych Source Type: news

Johnson & Johnson will appeal $4.7B powder award
Johnson& Johnson says it will "pursue all available appellate remedies" to reverse a St. Louis court verdict that awarded $4.7 billion to women who alleged that using the company ’s baby powder caused their ovarian cancer.  In a prepared statement, J&J (NYSE:JNJ) contends that the lawsuit filed on behalf of 22 women should not have been heard in Missouri because many of the women were not from the state.   Company spokeswoman Carol Goodrich predicted a reversal, saying, “The multiple errors… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - July 16, 2018 Category: Pharmaceuticals Authors: Anne Stych Source Type: news

Johnson & Johnson baby powder lawsuit ends with $4.7B award
Johnson& Johnson was ordered to pay $4.7 billion to 22 women and their families who say the company's talcum powder contributed to their ovarian cancer. The New Brunswick, New Jersey-based company (NYS: JNJ) has faced charges that its talc-based products contain asbestos. The trial was brought forward by women who contend that J&J-branded baby powder contained the cancer-causing substance dating back at least to the 1970s. They also contend that J&J knew its talc was contaminated but failed to … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 16, 2018 Category: American Health Authors: Anthony Noto Source Type: news

Ovarian cancer symptoms: Five common warning signs you might have the condition
OVARIAN cancer symptoms and signs can be mis-diagnosed as signals of a less serious condition, such as irritable bowel syndrome and pre-menstrual syndrome. Watch out for these five warning signs of the cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - July 14, 2018 Category: Consumer Health News Source Type: news

Johnson & Johnson still battling thousands of cases involving its baby powder
Some women claim the company's talcum powder caused their ovarian cancer (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 13, 2018 Category: Consumer Health News Source Type: news

Ovarian cancer risk from using talc, women warned
WOMEN should avoid using talcum powder because of the increased risk of ovarian cancer, a UK charity has warned. The advice comes after a US court ordered pharmaceutical giant Johnson& Johnson to pay damages of £3.6billion to a group of 22 women who blame the company for their condition. (Source: Daily Express - Health)
Source: Daily Express - Health - July 13, 2018 Category: Consumer Health News Source Type: news

Jury Orders J & J to Pay $550 Mln in Missouri Asbestos Cancer Case Jury Orders J & J to Pay $550 Mln in Missouri Asbestos Cancer Case
A Missouri jury on Thursday found Johnson& Johnson liable in a lawsuit filed by 22 women who alleged the company's talc-based products, including J&J Baby Powder, contain asbestos and caused them ovarian cancer, and ordered the company to pay $550 million in compensatory damages.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

J & J vows to overturn $4.7 billion talc verdict but experts see hurdles
Johnson& Johnson has vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company's products gave them ovarian cancer by arguing the plaintiffs' science was flawed and the case should not have been heard in Missouri. (Source: Reuters: Health)
Source: Reuters: Health - July 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Jury Awards $4.7 Billion To Women In Talcum Powder Lawsuit
(CNN) — After 8 hours of deliberations Thursday, a St. Louis jury awarded $4.69 billion to 22 women who sued pharmaceutical giant Johnson & Johnson alleging their ovarian cancer was caused by using its powder as a part of their daily feminine hygiene routine. The jury award includes $550 million in compensatory damages and $4.14 billion in punitive damages. It’s the largest verdict against the company that has sold Baby Powder and Shower to Shower brand talcum powder for decades. The jurors sat through weeks of testimony listening to experts who explained the complicated science, workers at Johnson & Jo...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - July 13, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Johnson & Johnson Local TV Source Type: news

Jury Awards $4.62B in Johnson & Johnson Talcum Powder Lawsuit
FRIDAY, July 13, 2018 -- A jury says Johnson& Johnson must pay $4.62 billion to 22 women who allege they developed ovarian cancer after using the company's Baby Powder and Shower to Shower brand talcum powder as part of their daily feminine... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 13, 2018 Category: Pharmaceuticals Source Type: news

Jury Awards & #36;4.62B in Johnson & amp; Johnson Talcum Powder Lawsuit
FRIDAY, July 13, 2018 -- A jury says Johnson& Johnson must pay $4.62 billion to 22 women who allege they developed ovarian cancer after using the company's Baby Powder and Shower to Shower brand talcum powder as part of their daily feminine... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 13, 2018 Category: Pharmaceuticals Source Type: news

J & J Hit with $4.7B Verdict in Talc Asbestos Cancer Case
A Missouri jury Thursday ordered Johnson & Johnson to pay $4.69 billion to 22 women who claim asbestos in the company’s talc products caused them to develop ovarian cancer. It is the largest verdict to date the consumer goods giant has faced in an asbestos-talc case. The Circuit Court of the City of St. Louis handed down $550 million in compensatory damages and $4.14 billion in punitive damages in the verdict, averaging about $25 million apiece for the 22 plaintiffs. J&J currently faces roughly 9,000 cases that blame its talc products — including the company’s iconic Johnson’s Baby Powder &m...
Source: Asbestos and Mesothelioma News - July 13, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Johnson & Johnson to pay $4.7B in damages to users of talc products
Johnson& Johnson was ordered Thursday to pay $4.7 billion to 22 women and their families who say the company's talcum powder contributed to their ovarian cancer. The New Brunswick, New Jersey-based company (NYS: JNJ) has faced charges that its talc-based products contain asbestos. The trial was brought forward by women who contend that J&J-branded baby powder contained the cancer-causing substance dating back at least to the 1970s. They also contend that J&J knew its talc was contaminated but … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 13, 2018 Category: American Health Authors: Anthony Noto Source Type: news

J & J loses one of the largest product-defect cases in U.S. history
Johnson& Johnson has been ordered to pay $4.69 billion to women who argued in court that its talc products contained asbestos, causing them to develop ovarian cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 13, 2018 Category: Pharmaceuticals Source Type: news

Nearly $4.7 billion awarded in Johnson & Johnson baby powder lawsuit
22 women and their families claimed asbestos in company's talcum powder contributed to their ovarian cancer; J&J will appeal (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 13, 2018 Category: Consumer Health News Source Type: news

Johnson & Johnson ordered to pay nearly $4.7B in ovarian cancer case
A jury in St. Louis, Mo., has awarded nearly $4.7 billion US in total damages to 22 women and their families after they claimed asbestos in Johnson & Johnson talcum powder contributed to their ovarian cancer, in the first case against the company that focused on asbestos in the powder. (Source: CBC | Health)
Source: CBC | Health - July 13, 2018 Category: Consumer Health News Tags: News/World Source Type: news

$4.69 billion verdict against Johnson & Johnson's talcum powder
After 8 hours of deliberations Thursday, a St. Louis jury awarded $4.62 billion to 22 women who sued pharmaceutical giant Johnson& Johnson alleging their ovarian cancer was caused by using its powder as a part of their daily feminine hygiene routine. (Source: CNN.com - Health)
Source: CNN.com - Health - July 13, 2018 Category: Consumer Health News Source Type: news

Jury slams J & J with almost $4.7B tab in talcum powder suit
22 women and their families claimed asbestos in company's talcum powder contributed to their ovarian cancer; J&J will appeal (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - July 13, 2018 Category: Consumer Health News Source Type: news